ENDRA Life Sciences regains Nasdaq compliance; subject to one-year monitor

ENDRA Life Sciences Inc.

Nasdaq notified ENDRA on July 8, 2026 that it regained compliance with the $2.5M Minimum Stockholders' Equity Requirement.
Company had been below requirement; requested hearing on April 27, 2026, hearing held May 28, 2026.
Subject to Discretionary Panel Monitor for one year from July 1, 2026.
If non-compliant again during monitor period, no cure period; immediate delisting process begins.
Company can request a new hearing if a delisting determination is issued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.